AbbVie Earnings Call Transcripts
Fiscal Year 2026
-
First quarter 2026 delivered strong growth, with adjusted EPS and revenues exceeding expectations. Upgraded full-year guidance reflects robust performance in immunology, neuroscience, and pipeline progress, supported by strategic investments and business development.
-
Management projects robust growth through the decade, driven by strong performance in immunology and neuroscience, with SKYRIZI and RINVOQ leading. Multiple pivotal readouts are expected this year across immunology, oncology, and neuroscience, while disciplined R&D and business development support long-term growth.
-
Management highlighted robust R&D progress, including positive late-stage data in immunology and IBD, and a diversified pipeline in neuroscience, oncology, and obesity. Financial outlook remains strong with high single-digit growth projected through 2029, supported by increased R&D investment and strategic acquisitions.
-
Lutikizumab and RINVOQ are advancing in HS with strong phase II data and a focus on clinical differentiation. In IBD, combination strategies with SKYRIZI, TL1A, and novel mechanisms like TREM1 are prioritized, while next-generation oral and B-cell therapies expand the pipeline.
-
Operational execution and pipeline advancement remain top priorities, with strong growth in immunology and neuroscience expected to drive high single-digit revenue CAGR through the decade. The company is investing in innovation, expanding its pipeline, and adapting to evolving market and regulatory dynamics.
Fiscal Year 2025
-
Record 2025 sales and EPS exceeded guidance, driven by strong growth in immunology and neuroscience. 2026 outlook projects 9.5% revenue growth, robust free cash flow, and continued pipeline advancement, despite ongoing Humira erosion and pricing headwinds.
-
Management emphasized a strategy of smaller, targeted deals to drive long-term growth, with robust R&D investment and margin expansion projected through 2029. Skyrizi and Rinvoq continue to lead in IBD and dermatology, while neuroscience and novel therapies like brotosilicin are poised for significant growth.
-
Panelists highlighted rising vaccine hesitancy, the importance of trusted local voices, and the need for creative global access strategies. Advances in immunology, AI, and surveillance are shaping the next generation of vaccines, while speed and stakeholder engagement are critical for successful launches.
-
Adjusted EPS and revenues exceeded expectations, driven by strong growth in immunology and neuroscience. 2025 guidance was raised, with robust pipeline progress and increased R&D investment, despite ongoing HUMIRA erosion and aesthetics market softness.
-
Management highlighted active policy engagement, robust growth in immunology, and strong new product launches. Strategic investments in manufacturing, neuroscience, and early-stage assets support long-term growth, while stable pricing and market access are expected through 2026.
-
Second quarter results exceeded expectations with strong growth in immunology and neuroscience, leading to raised full-year revenue and EPS guidance. Robust performance from SKYRIZI and RINVOQ, pipeline advancements, and strategic business development support a positive long-term outlook.
-
Productive policy engagement and robust financial performance support a strong growth outlook, with immunology, neuroscience, and oncology franchises driving momentum. Early-stage business development and pipeline innovation, especially in obesity and aesthetics, position the company for long-term expansion.
-
Management is proactively addressing policy risks, maintaining strong commercial and supply chain strategies, and expanding its pipeline through targeted M&A. The company is entering the obesity market with a differentiated asset and expects continued growth in immunology, supported by product innovation and market expansion.
-
Shareholders reviewed strong 2024 financials, approved director elections, auditor, and executive compensation, but did not pass proposals to eliminate supermajority voting. The company increased its dividend, advanced its pipeline, and outlined strategic investments for long-term growth.
-
First-quarter results surpassed expectations with strong growth in immunology, neuroscience, and oncology, while aesthetics faced macro headwinds. Full-year guidance was raised for key products and overall EPS, supported by robust pipeline progress and strategic investments.
-
Leaders outlined a strategy focused on five growth platforms, with Skyrizi and Rinvoq driving immunology gains and a robust neuroscience and oncology pipeline. R&D investment is rising, highlighted by a new obesity program and multiple late-stage assets, supporting high single-digit growth through the decade.
-
Management highlighted robust growth through the decade, driven by a diverse late-stage pipeline in immunology, neuroscience, oncology, and eye care. Recent acquisitions and new indications are expected to add significant value, while margin expansion and underappreciated assets in migraine and oncology offer further upside.
-
Management projects robust growth through 2029, driven by immunology, oncology, and neuroscience, with Skyrizi and Rinvoq leading market share gains. Early-stage pipeline investments and innovation in aesthetics and neuroscience support long-term growth, despite near-term challenges in legacy products and aesthetics.
Fiscal Year 2024
-
Full-year adjusted EPS and revenues exceeded guidance, driven by strong growth in ex-Humira assets, especially Skyrizi and Rinvoq. 2025 guidance calls for robust operational growth despite Medicare Part D headwinds, with continued pipeline expansion and prudent capital allocation.
-
Ex-Humira business delivered strong growth in 2024, led by Skyrizi and Rinvoq, with robust momentum expected into 2025 despite ongoing Humira erosion. Pipeline progress in neuroscience and oncology, plus innovation in aesthetics, support long-term growth across key therapeutic areas.
-
Q3 delivered strong sales and EPS growth, driven by Skyrizi and Rinvoq, offsetting Humira declines. Guidance for revenue and EPS was raised, with robust performance across immunology, oncology, and neuroscience, while aesthetics faced headwinds from economic conditions.
-
Q2 2024 saw strong operational sales growth, led by immunology and oncology, with ex-HUMIRA assets outperforming expectations. Full-year guidance was raised for both revenue and EPS, while aesthetics guidance was moderated due to market headwinds, but long-term growth outlook remains robust.
-
Ex-Humira assets now drive over 80% of revenue, supporting a return to growth and above-industry-average expectations for 2025 and beyond. Skyrizi and Rinvoq lead immunology, with robust expansion in neuroscience, oncology, and aesthetics, while business development and innovation remain key priorities.